Pricing Log in Create free account
Saturday 7 November 2026 Export ACET’s income statement to Excel — free account

Adicet Bio, Inc.

ACET Healthcare Biotechnology

Adicet Bio, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $25.0 million.

EPS
+63.4%
Free cash flow
+24.9%

Quarter to June 2026, against a year earlier

3.05 0.13 +4.45%
Market cap
$27.3M
P/E
0.0×
Fwd P/E
−0.4×
Dividend yield
—
F-score
4/9
Altman Z
4.96
Beneish M
n/a
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Bought, $m 1.60
Sold, $m 0.67
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — 1 — — — — — — — — —
Sell — — — — 1 — — — — — — —
Insider Ownership 23.50%

Capital & Financial Ratios $m

Size
Market Cap 27.33
Revenue ttm 38.70
Net income ttm (98.97)
Free cash flow ttm (84.97)
Net debt Q (117.56)
Valuation
P/E 0.00
Forward P/E (0.43) (negative: loss-making)
Price / sales 0.85
Forward P/S Powerpack
Price / FCF 0.00
Price / book 0.27
Financial health
Current ratio Q 6.71 (at or above 1.5: strong)
Debt / equity Q 0.01 (at or below 0.5: strong)
Interest coverage Q (1,013.68)
Growth
Revenue growth Q +727.73% (above 0%: growing)
Operating income growth Q +31.15% (above 0%: growing)
EPS, this year +60.58% (at or above 15%: strong)
EPS, next year A +26.47% (at or above 15%: strong)
Revenue, next year A −90.00% (below 0%: weak)
EPS, past 5 yrs —
EPS, next 5 yrs A +41.54% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is −2.2×, against a ten-year median of −1.0×; over the ten years it ranged from −3.6× in 2020 to 29.1× in 2021.
P/S against its own 10 years 0.13%
10-year low 10-year high
P/B against its own 10 years 3.71%
10-year low 10-year high
EV/FCF against its own 10 years 56.86%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—
Growth, 2016–23
−100.0%/yr
  1. 0.25 ’16
  2. 0.26 ’17 +4
  3. 0.09 ’18 −67
  4. 0.00 ’19 −100
  5. 0.00 ’20
  6. 0.00 ’21
  7. 0.00 ’22
  8. 0.00 ’23
paid change on the year, %

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 160 176 159 118
Receivables — — — —
Inventory — — — —
Other — — — —
162 180 161 121
2023 2024 2025 Q'26
Payables 3 5 5 4
ST’ Debt — — — —
Other 13 11 — —
19 19 22 18

Compound Annual Growth %

10y 5y 3y
Sales — 6.90% 192.85%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 0.00% 7.71% (18.34%)

Earnings Trends EPS, adjusted, against the consensus

Q3 FY26 Estimate −1.56 Actual −1.76

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q4 FY25 −3.23 −2.94 Beat by 0.29
Q1 FY26 −2.93 −1.88 Beat by 1.05
Q2 FY26 −2.43 −1.99 Beat by 0.44
Q3 FY26 −1.56 −1.76 Miss by 0.20
Q4 FY26 −1.59 — Reports 11 March 2027

EPS $

Mar Jun Sep Dec Year
’26 (1.88) (1.99) — — —
’25 (4.96) (5.44) (4.64) (2.94) (16.95)
’24 (5.60) (5.28) (5.44) (5.12) (21.28)
’23 (11.52) (12.00) (18.56) (11.04) (52.96)
’22 1.60 (8.96) (8.48) (11.52) (27.20)
’21 (13.12) (5.44) (7.04) (7.52) (32.00)
’20 (33.18) (62.14) (45.44) (7.36) (80.16)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 — — — — —
’22 25 — — — 25
’21 (4) 5 3 5 10
’20 2 7 3 5 18
’19 — — (7) 8 1
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (21) (20) — — —
’25 (25) (27) (22) (21) (95)
’24 (23) (23) (22) (24) (92)
’23 (24) (25) (21) (23) (94)
’22 4 (15) (15) (19) (45)
’21 (15) (13) (10) (13) (51)
’20 (8) (12) (8) (13) (42)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (22) (20) — — —
’25 (27) (27) (23) (21) (97)
’24 (23) (24) (22) (24) (93)
’23 (26) (26) (22) (24) (98)
’22 1 (18) (20) (25) (62)
’22 — — — — (45)
’21 (16) (15) (17) (17) (64)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue — — 8 1 18 10 25 — — — 39 +32.2% 29 29 84 +72.1%
Gross margin, % — 0.00 100.00 100.00 100.00 100.00 100.00 — — — 0.00 +100.0 pt
EBT 0 (34) (10) (28) (39) (62) (70) (143) (117) (117) (99) n/m
EBT margin, % 0.00 0.00 (120.87) (2,826.03) (220.59) (638.48) (279.27) 0.00 0.00 0.00 0.00 0.0 pt
Net income 0 (34) (9) (28) (37) (62) (70) (143) (117) (117) (99) n/m
Per share, $
Per share, $ Revenue 0.00 0.00 67.22 7.44 39.13 5.03 9.73 0.00 0.00 0.00 0.00 n/m
Earnings 0.00 (942.76) (76.42) (210.48) (80.16) (32.00) (27.20) (52.96) (21.28) (16.95) (11.45) n/m
Cash flow 0.00 (306.84) (149.38) (208.54) (90.82) (26.39) (17.44) (34.84) (16.82) (13.82) (7.87) n/m
Capex 0.00 (1.23) (7.20) (7.12) (2.16) (6.74) (6.54) (1.66) (0.20) (0.25) (0.04) n/m
Free cash flow 0.00 (308.07) (156.58) (215.66) (92.99) (33.13) (23.97) (36.50) (17.02) (14.07) (7.91) n/m
Book value 0.00 (891.87) 856.24 (451.50) 240.06 156.70 113.86 63.26 33.98 23.10 11.18 n/m
Shares, m 4 0 0 0 0 2 3 3 5 7 9 +6.2%
Valuation, ×
Valuation, × P/E — — 0.00 0.00 0.00 0.00 0.00 — — — 0.00 0.0
P/S — — 0.00 0.00 5.74 55.64 9.10 — — — 0.85 14.1
P/B — — 1.13 0.00 0.94 1.79 1.20 — — — 0.27 1.0
EV/Sales — — 0.00 0.00 1.60 29.10 2.92 — — — (2.19) 6.7
EV/FCF — — (0.50) 1.39 (0.67) (4.42) (1.83) — — — 1.00 (1.2)
Cash, $m
Cash, $m Operating cash flow 0 (11) (18) (28) (42) (51) (45) (94) (92) (95) (85) n/m
Capex 0 0 (1) (1) (1) (13) (17) (4) (1) (2) 0 n/m
Free cash flow 0 (11) (19) (29) (43) (64) (62) (98) (93) (97) (85) n/m
Balance, $m
Balance, $m Working capital — 50 104 49 78 266 241 143 161 139 103 +13.8%
Net debt — (53) (108) (62) (95) (278) (258) (160) (176) (158) (118) +14.5%
Shareholders’ equity — (32) 104 (60) 110 303 292 170 187 159 120 n/m
Returns, %
Returns, % ROA 0.00 (122.40) (11.26) (29.38) (31.16) (25.16) (20.84) (53.03) (54.79) (56.62) (63.62) (56.6) pt
ROIC — 0.00 0.00 0.00 (161.01) (150.07) (130.74) (908.10) (773.91) (5,773.17) (2,518.16) (5,773.2) pt
ROE 0.00 105.79 (25.73) (128.37) (148.31) (30.03) (23.44) (61.69) (65.65) (67.55) (78.08) (67.5) pt
People
People Employees 7 7 21 18 102 102 132 143 152 102 — +34.7%
Revenue/emp, $m 0.00 0.00 0.39 0.06 0.18 0.10 0.19 0.00 0.00 0.00 — n/m
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2022 · latest quarter Mar 2022

Adicet Bio, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
EDSA Edesa Biotech, Inc. $28.8M — (loss-making) — (loss-making) −99.88% (below 0%: shrinking) n/m −81.24% (below 0%: shrinking) 0.00% 0.00% Compare
ANVS Annovis Bio, Inc. $28.6M — (loss-making) — — n/m −329.18% (below 0%: shrinking) — 0.00% Compare
BCTX BRIACELL THERAP $28.6M — (loss-making) — — n/m +26.73% (above 0%: growing) 0.00% 0.00% Compare
ALGS Aligos Therapeutics, Inc. $28.2M — (loss-making) — (loss-making) +287.18% (above 0%: growing) n/m +105.91% (above 0%: growing) 100.00% (762.98%) Compare
MGX Metagenomi Therapeutics, Inc. $27.6M — (loss-making) — (loss-making) −103.02% (below 0%: shrinking) n/m +7.98% (above 0%: growing) 100.00% 11,195.72% Compare
PLRZ Polyrizon Ltd. $27.5M — — — — −744.51% (below 0%: shrinking) — — Compare
ACET Adicet Bio, Inc. $27.3M — (loss-making) — (loss-making) +727.73% (above 0%: growing) n/m +24.94% (above 0%: growing) 0.00% 0.00%
BYSI BeyondSpring Inc. $26.0M — (loss-making) — (loss-making) +87.78% (above 0%: growing) n/m +35.78% (above 0%: growing) 100.00% 0.00% Compare
ABVC ABVC BioPharma, Inc. $25.9M — (loss-making) — (loss-making) +66,233.33% (above 0%: growing) n/m +72.66% (above 0%: growing) 100.00% 0.00% Compare
Median of peers $27.9M — — +87.78% — +17.35% 100.00% 0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 29 April 2026

Chief executive’s pay

Year Total pay Actually paid $100 invested
2025 1.47m 347.82k 5.89
2024 4.64m 2.55m 10.76
2023 5.97m (498.11k) 21.14

Ownership

Directors and executive officers, together 3.40%
RA Capital Healthcare Fund, L.P. 9.90%
Entities affiliated with OrbiMed 9.00%
Franklin Resources, Inc. 6.70%
Woodline Partners LP 6.70%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Adicet Bio, Inc. (ACET) Latest News

5 Nov

Impact 4 · · Business WireGuruFocus.comGuruFocus.comGuruFocus.comMotley Fool
Impact 3 · · Business Wire

2 Oct

Impact 4 · · MarketBeat

28 Sep

Impact 4 · · InvestorsHub
Impact 4 · · InvestorsHub
Impact 4 · · Business Wire

25 Sep

Impact 3 ·

1 Sep

Impact 3 ·

27 Aug

Impact 4 ·

24 Aug

Impact 3 ·

14 Aug

Impact 3 ·

11 Aug

Impact 4 · · MarketBeat
Impact 4 ·

10 Aug

Impact 3 ·

5 Aug

Impact 3 ·

4 Jun

Impact 3 · · MarketBeat

13 May

Impact 3 · · Business Wire

12 Mar

Impact 3 · · Business Wire

30 Jan

Impact 3 · · Business WirePharmaceutical TechnologySimply Wall St.Insider Monkey

7 Jan

Impact 4 · · Business Wire

26 Dec

Impact 3 · · Business Wire

16 Oct

Impact 4 · · Business Wire

7 Oct

Impact 4 · · Business Wire
Impact 3 ·

30 Sep

Impact 4 ·

2 Sep

Impact 3 ·

12 Aug

Impact 4 ·

7 Aug

Impact 3 · · Business Wire

6 Aug

Impact 3 ·

4 Aug

Impact 4 · · GlobeNewswire
stockrow.com/ACET · Data as of Mar 31, 2022 · For information only; not investment advice. · © 2026 stockrow.com